| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Trilostane (also known as WIN 24540; Desopan; DB-011080; Win-24540; Modrastane) is a potent inhibitor of 3β-hydroxysteroid dehydrogenase that was used in the treatment of Cushing's syndrome, Conn's syndrome, and postmenopausal breast cancer in humans. However, Trilostane was withdrawn from the United States in the 1990s and was later approved as a veterinary medicine for use in the treatment of Cushing's syndrome in dogs.
| ln Vitro |
Adrenocortical pregnenolone metabolism is impacted by trilostane in a time- and dose-dependent way [2]. Trilostane specifically prevents the adrenal gland from converting pregnenolone to progesterone [2].
|
|---|---|
| ln Vivo |
Dogs with pituitary-dependent elevated adrenocortical hormone levels are managed with trimostane (5.3–50 mg/kg; PO once daily for three months) [1].
|
| Animal Protocol |
Animal/Disease Models: Dogs with naturally-occurring pituitary-dependent hyperadrenocorticism (PDH)[1]
Doses: 5.3-50 mg/kg Route of Administration: Oral administration; 5.3-50 mg/kg, one time/day for 3 months Experimental Results: Effectively achieved endocrine control with safe effects and free of side-effects. |
| References |
[1]. JA Braddock, et al. Trilostane treatment in dogs with pituitary-dependent hyperadreno-corticism. Veterinary Journal. 10 March 2008.
[2]. Ouschan C, et al. The influence of trilostane on steroid hormone metabolism in canine adrenal glands and corpora lutea-an in vitro study. Vet Res Commun. 2012 Mar;36(1):35-40. |
| Molecular Formula |
C20H27NO3
|
|
|---|---|---|
| Molecular Weight |
329.43
|
|
| CAS # |
13647-35-3
|
|
| Related CAS # |
Trilostane-d3
|
|
| SMILES |
O1[C@]2([H])C(=C(C#N)C([H])([H])[C@]3(C([H])([H])[H])[C@@]4([H])C([H])([H])C([H])([H])[C@]5(C([H])([H])[H])[C@]([H])(C([H])([H])C([H])([H])[C@@]5([H])[C@]4([H])C([H])([H])C([H])([H])[C@]132)O[H])O[H]
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0355 mL | 15.1777 mL | 30.3555 mL | |
| 5 mM | 0.6071 mL | 3.0355 mL | 6.0711 mL | |
| 10 mM | 0.3036 mL | 1.5178 mL | 3.0355 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA